Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Metal containing – e.g. – chromoproteins – ferritin,...
Reexamination Certificate
2006-04-25
2006-04-25
Kerr, Kathleen M. (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Metal containing, e.g., chromoproteins, ferritin,...
C530S350000, C530S395000, C514S012200, C514S008100, C514S006900, C424S009100, C424S085100
Reexamination Certificate
active
07034126
ABSTRACT:
The present invention relates to methods of using a composition of lactoferrin for the treatment of diabetes mellitus as manifested by a reduction in the levels of serum glucose, blood pressure, obesity, or glycosylated hemoglobin (HbAlc).
REFERENCES:
patent: 4200435 (1980-04-01), Stroupe et al.
patent: 5240909 (1993-08-01), Nitsche
patent: 5576299 (1996-11-01), Ando et al.
patent: 5919913 (1999-07-01), Nuyens et al.
patent: 6066469 (2000-05-01), Kruzel et al.
patent: 6080559 (2000-06-01), Conneely et al.
patent: 6100054 (2000-08-01), Conneely et al.
patent: 6228614 (2001-05-01), Conneely et al.
patent: 6277817 (2001-08-01), Kruzel et al.
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 6455687 (2002-09-01), Kruzel et al.
patent: 6613741 (2003-09-01), Kruzel et al.
patent: 2002/0064524 (2002-05-01), Cevc
patent: 2002/0111295 (2002-08-01), Yajima et al.
patent: 2002/0119928 (2002-08-01), Mcanalley
patent: 2002/0160359 (2002-10-01), Steaffens et al.
patent: 2003/0039651 (2003-02-01), Olmarker
patent: 2003/0074700 (2003-04-01), Huang et al.
patent: 2003/0077641 (2003-04-01), Laskowitz et al.
patent: 2003/0096763 (2003-05-01), Kruzel et al.
patent: 8165248 (1996-06-01), None
patent: WO 91/13982 (1991-09-01), None
patent: WO-0049040 (2000-08-01), None
patent: WO-0172322 (2001-10-01), None
patent: WO-0203910 (2002-01-01), None
patent: WO-0241912 (2002-05-01), None
patent: WO-02080891 (2002-10-01), None
patent: WO-03061688 (2003-07-01), None
Birgisdottir et al., “Variation in Consumption of cow Milk Proteins and Lower Incidence of Type 1 Diabetes in Iceland vs the other 4 Nordic Countries,” DNM vol. 15, No. 4, p. 240-245, 2002.
Zagulski et al, “Lactoferrin Stimulates Killing and Clearance of Bacteria but Does Not Prevent Mortality of Diabetic Mice,” Archivum Immunologist et Therapiae Experimentalis vol. 49, p. 431-438, 2001.
Thomalley, Paul J., “Cell Activation by Glycated Proteins Age Receptors, Receptor Recognition Factors and Functional Classification of Ages,” Cellular and Molecular Biology vol. 44 No. 7, pp. 1013-1023, 1998.
Li, Yong Ming, “Glycation Ligand Binding Motif in Lactoferrin,” Advances in Lactoferrin Research Chapter 7, pp. 57-63, 1998.
Jurado, Rafael, “Iron, Infections and Anemia of Inflammation,” Clinical Infectious Diseases vol. 25, p. 888-895, 1997.
Li et al, “Antibacterial Activity of Lysozyme and Lactoferrin is Inhibited by Binding of Advanced Glycation-modified Proteins to a Conserved Motif,” Nature Medicine vol. 1 No. 10, Oct. 1995, pp. 1057-1061.
Schmidt et al, “The Dark Side of Glucose,” Nature Medicine vol. 1 No. 10, Oct. 1995, pp. 1002-1004.
Schmidt et al, “Cellular Receptors for Advanced Glycation End Products,” Arterioscler Thromb vol. 14, 1994, pp. 1521-1528.
Yan et al, “Enhanced Cellular Oxidant Stress by the Interaction of Advanced Glycation End Products with Their Receptors/Binding Proteins,” The Journal of Biomedical Chemistry vol. 269, No. 13, Apr. 1, 1994, pp. 9889-9897.
Butte et al, “Milk Composition of Insulin Dependent Diabetic Women,” Journal of Pediatric Gastroenterology and Nutrition vol. 6, 1987, pp. 936-941.
Tabak et al, “Alterations in Lactoferrin in Salivary Gland Disease,” J. Dent Res 57(1), Jan. 1978; pp. 43-47.
Birgisdottir et al., “Variation in Consumption of cow Milk Proteins and Lower Incidence of Type 1 Diabetes in Iceland vs the other 4 Nordic Countries,” DNM vol. 15, No. 4, p. 240-245, 2002.
Zagulski et al, “Lactoferrin Stimulates Killing and Clearance of Bacteria but Does Not Prevent Mortality of Diabetic Mice,” Archivum Immunologist et Therapiae Experimentalis vol. 49, p. 431-438, 2001.
Thomalley, Paul J., “Cell Activation by Glycated Proteins Age Receptors, Receptor Recognition Factors and Functional Classification of Ages,” Cellular and Molecular Biology vol. 44 No. 7, pp. 1013-1023, 1998.
Li, Yong Ming, “Glycation Ligand Binding Motif in Lactoferrin,” Advances in Lactoferrin Research Chapter 7, pp. 57-63, 1998.
Jurado, Rafael, “Iron, Infections and Anemia of Inflammation,” Clinical Infectious Diseases vol. 25, p. 888-895, 1997.
Li et al, “Antibacterial Activity of Lysozyme and Lactoferrin Is Inhibited by Binding of Advanced Glycation-modified Proteins to a Conserved Motif,” Nature Medicine vol. 1 No. 10, Oct. 1995, pp. 1057-1061.
Schmidt et al, “The Dark Side of Glucose,” Nature Medicine vol. 1 No. 10, Oct. 1995, p. 1002-1004.
Schmidt et al, “Cellular Receptors for Advanced Glycation End Products,” Arterioscler Thromb vol. 14, 1994, pp. 1521-1528.
Yan et al, “Enhanced Cellular Oxidant Stress by the Interaction of Advanced Glycation End Products with Their Receptors/Binding Proteins,” The Journal of Biomedical Chemistry vol. 269, No. 13, Apr. 1, 1994, pp. 9889-9897.
Butte et al, “Milk Composition of Insulin Dependent Diabetic Women,” Journal of Pediatric Gastroenterology and Nutrition vol. 6, 1987, pp. 936-941.
Tabak et al, “Alterations in Lactoferrin in Salivary Gland Disease,” J Dent Res 57(1), Jan. 1978; pp. 43-47.
Hayashida et al, “Novel function of bovine milk-derived lactoferrin on antinociception mediated by M-opioid receptor in the rat spinal cord,” Brain research 965, 2003, pp 239-245.
Baraniuk et al, “Hypertonic Saline Nasal Provocation Stimulates Nociceptive Nerves, Substance P Release, and Glandular Mucous Exocytosis in Normal Humans,” Am J Respir Crit care Med vol. 160, 1999, pp. 655-662.
Eckmann, L. “Mucosal defences against Giardia,” Parasite Immunol. vol. 25 No. 5, May 2003, pp 259-270.
Hayashida et al, “Lactoferrin enhances opioid-mediated analgesia via nitric oxide in the rat spinal cord,” Am J Physiol Regul Integr Com Physiol 285, 2003; R306-R312.
Teschemacher, Hansjorg “Latoferrin elicits opioid-mediated antinociception without development of toleence: central nNOS-1 set off duty?” American Journal Physiol. Regul Integr Comp Physiol 285, 2003, R302-R305.
McClead et al, “Oral Lactoferrin and Lactoperoxidase decrease Mortality of EnterotoxigenicE coli.Infenction,” Pediatric Research 1987, vol. 21, No. 4 Part 2, pp 417A.
Lee et al, “The Protective Effects of Lactoferrin Feeding against Endotoxin Lethal Shock In Germfree Piglets,” Infection and Immunity vol. 66 No. 4, 1998, pp. 1421-1426.
Kruzel et al, “Lactoferrin and insult induced metabolic imbalance in humans and other animals,” International Congress Series 2000, 1195, pp. 301-310.
Edde et al, “Lactoferrin Protects Neonatal Rats from Gut-related Systemic Infection,” Am J Physiol Gastrointest Liver Phsyiol 281: G1140-G1150, 2001.
Engelmayer Jose
Varadhachary Atul
Acosta Melissa W.
Agennix Inc.
Fulbright & Jaworski
Kam Chih-Min
Kerr Kathleen M.
LandOfFree
Lactoferrin in the treatment of diabetes mellitus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactoferrin in the treatment of diabetes mellitus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactoferrin in the treatment of diabetes mellitus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3582581